TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01017952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 Inhalation Powder
Description: Long Acting Beta Agonist(LABA) Inhalation Powder
Study: NCT03804684

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Automatic Perimetry Humphrey Field Analyzer
Description: Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Automatic Perimetry Humphrey Field Analyzer
Description: Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: visuALL Field Analyzer
Description: visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: visuALL Field Analyzer
Description: visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
Study: NCT00954278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
Study: NCT03598855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: Ischemic preconditioning (IPC) refers to cycles of 5 minutes of upper arm cuff inflation with 5 minute periods of cuff deflations, repeated 4 times.
Study: NCT01707849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVL arm
Description: Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF arm
Description: Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
Study: NCT04248738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEEDS
Description: NEEDS intervention includes assessing patients' social needs and resources (SocNSuppR) and communicating those SocNSuppR to discharge teams
Study: NCT00809107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: 5000IU
Study: NCT01472887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR3419
Description: Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous
Study: NCT01924208

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Timothy, Phleum pretense
Description: Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Timothy, Phleum pretense
Description: Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated influenza virus
Description: Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated influenza virus
Description: Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timothy + attenuated influenza virus
Description: Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
Study: NCT00361634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Study: NCT04263584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib vials 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Chemotherapy
Description: Immunochemotherapy
Study: NCT04650451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor (CAR) T cell therapy
Description: HER2-targeted dual-switch CAR-T cells
Study: NCT01561898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (JNS007ER)
Description: Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
Study: NCT04230252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Study: NCT04329338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus pentosus KCA1
Description: Lactobacillus pentosus KCA1 suspended in dairy and taken orally for 14 days
Study: NCT03605628

Intervention type: OTHER
Group type: OTHER
Intervention: measuring tape
Description: measurement of change in abdominal wall length \[cm\] during neuromuscular block with a measuring tape.

Intervention type: OTHER
Group type: OTHER
Intervention: neuromuscular block
Description: Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);

Intervention type: OTHER
Group type: OTHER
Intervention: Surgical rating score
Description: assessment of operating conditions by means of a standardized score: surgical rating score:~1. extremely poor conditions~2. poor conditions~3. acceptable conditions~4. good conditions~5. optimal conditions
Study: NCT02646241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unroofing biopsy
Description: Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)
Description: EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB \& unroofing biopsy.
Study: NCT01924208

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timothy + attenuated influenza virus
Description: Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
Study: NCT01178658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, etoposide, cytarabine, and melphalan
Description: Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
Study: NCT01251783

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Description: Only Infant Formula without Lactobacillus, Metlin OR Metlos

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Exclusively breast milk
Description: Children non randomized which mothers decided to feed them with exclusively breast milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metlin+metlos+Lactobacillus GG
Description: A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metlin + Lactobacillus GG
Description: A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
Study: NCT02532699

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AC mycelia
Description: An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
Study: NCT03745599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzydamine
Description: All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
Study: NCT04204551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training (HIIT)
Description: Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 \[rpm\], but preferably at 80-90 \[rpm\] (fast phase of interval) and 2-minutes cycling at ≤ 60 \[rpm\] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, \[bpm\]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
Study: NCT01251783

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metlos + lactobacillus GG
Description: A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG
Description: An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
Study: NCT04388306

Intervention type: OTHER
Intervention: Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)
Description: Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.

Intervention type: OTHER
Intervention: Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)
Description: Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.
Study: NCT04431115

Intervention type: OTHER
Intervention: Interviews
Description: Interviews for stakeholders

Intervention type: OTHER
Intervention: Interviews
Description: Interviews for stakeholders

Intervention type: OTHER
Intervention: Interviews
Description: Interviews for stakeholders
Study: NCT02713568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound examination
Description: Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.~Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.~For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance examination
Description: MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.~Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031\*Fetal Body Volume = MR imaging weight (g) developed by Baker.~General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.~For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99.
Study: NCT01990287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS and PNfS
Description: Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCS Alone
Description: Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
Study: NCT04001855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dilute vinegar (acetic acid)
Description: Dilute vinegar baths or gauze soaks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dilute vinegar (acetic acid)
Description: Dilute vinegar baths or gauze soaks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dilute bleach
Description: Dilute bleach baths or gauze soaks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dilute bleach
Description: Dilute bleach baths or gauze soaks
Study: NCT02676687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total resection
Description: Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supratotal resection
Description: Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
Study: NCT01656434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NETA-EE
Description: NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol (EE)
Description: EE 10 μg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate
Description: ferrous fumarate 75 mg tablet
Study: NCT03940066

Intervention type: DEVICE
Group type: OTHER
Intervention: Biomonitor-2 and Kardia mobile
Description: Implantable cardiac monitor and Smart-phone based electrocardiogram recording

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT03213366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-PrEP- Peer-Led Intervention about PrEP
Description: Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BxNow - General Health Campaign
Description: BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
Study: NCT02112500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
Study: NCT00615615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg~* low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
Study: NCT01710488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 1 tablet 500 mg once a day
Description: Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 1 tablet 600 mg once a day
Description: Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.
Study: NCT00876083

Intervention type: DRUG
Intervention: Ultravist (Iopromide, BAY86-4877)
Description: Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
Study: NCT00151671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Impact®
Description: Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.